Table 2. Predictors of raltegravir effectiveness.

	ITT, n = 320, failure = 47			OT, n = 300, failure = 27
	Crude HR(95% CI)	Adjusted HR*(95% CI)		Crude HR(95% CI)	Adjusted HR*(95% CI)
Age (by 5 years)	0.90 (0.75–1.07)			0.91 (0.72–1.14)
Sex (Female vs Male)	1.00 (0.52–1.92)			1.22 (0.54–2.79)
HIV transmission category (IDU as reference)
Heterosexual	0.59 (0.25–1.41)			0.45 (0.13–1.65)
Male Homosexual	1.16 (0.62–2.17)			1.33 (0.59–3.00)
CDC stage C (Yes vs No)§	2.37 (1.30–4.33)		2.17 (1.14–4.11) P = 0.01	2.08 (0.95–4.54)	1.91 (0.86–4.27) P = 0.11
Log10 HIV RNA at baseline (by 1)	1.21 (0.94–1.57)			1.04 (0.74–1.46)
CD4 cell count (by 50 cells/mmc)§	0.89 (0.81–0.98)		0.92 (0.84–1.01) P = 0.06	0.94 (0.84–1.04)
Past ARV regimens (1–5 as reference)
6–8	0.85 (0.37–1.95)			0.97 (0.35–2.67)
9–12	1.04 (0.48–2.27)			0.88 (0.32–2.41)
≥13	0.95 (0.40–2.23)			0.60 (0.18–2.04)
ART duration before study entry (by 1 year)	1.00 (0.95–1.05)			1.03 (0.96–1.11)
HCV/HBV coinfection (Yes vs No)	0.97 (0.53–1.80)			1.04 (0.47–2.31)
Genotipic Sensitivity Score (by 1 point)	0.94 (0.65–1.36)			0.94 (0.59–1.52)

ITT  =  intention-to-treat analysis, OT  =  on-treatment analysis, IDU  =  intravenous drug user; ARV  =  antiretroviral; ART  =  antiretroviral therapy; HCV  =  Hepatitis C Virus; HBV  =  Hepatitis B Virus.

^*only including selected variables (P<0.15).

^§P<0.05.